Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 149.7% in the third quarter, HoldingsChannel.com reports. The fund owned 1,297,094 shares of the company’s stock after buying an additional 777,568 shares during the period. JPMorgan Chase & Co.’s holdings in Amneal Pharmaceuticals were worth $10,792,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in AMRX. Barclays PLC boosted its position in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after buying an additional 169,756 shares during the last quarter. State Street Corp grew its position in Amneal Pharmaceuticals by 3.8% during the third quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after buying an additional 127,753 shares during the period. Geode Capital Management LLC increased its holdings in Amneal Pharmaceuticals by 11.1% in the third quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock valued at $31,511,000 after buying an additional 378,136 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock valued at $778,000 after buying an additional 4,178 shares in the last quarter. Finally, Rubric Capital Management LP grew its stake in Amneal Pharmaceuticals by 12.4% in the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock valued at $68,083,000 after acquiring an additional 1,179,830 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares in the company, valued at $117,655.65. This represents a 76.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gautam Patel sold 17,410 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $8.01, for a total transaction of $139,454.10. Following the completion of the transaction, the director now owns 2,031,476 shares of the company’s stock, valued at approximately $16,272,122.76. This trade represents a 0.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 123,657 shares of company stock worth $1,016,687 over the last three months. Insiders own 26.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AMRX. Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, November 11th. Truist Financial raised their price target on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Wednesday, October 2nd. Finally, StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Down 1.1 %

Shares of NASDAQ:AMRX opened at $7.97 on Monday. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -11.72 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48. The business has a 50-day moving average price of $8.22 and a 200 day moving average price of $8.06.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.